Table 1.
Demographic and clinical data
| DYT-SGCE (n = 19) | HV (n = 24) | F (P) | |
|---|---|---|---|
| Agea (range) | 30.37 ± 2.68 (19–60) | 29.71 ± 2.15 (18–54) | 0.04 (0.85)* |
| Years of educationa | 13.94 ± 0.35 | 13.17 ± 0.37 | 2.20 (0.16)* |
| Laterality (R:L)b | 16:3 | 19:5 | 1.00** |
| Sex (F:M)b | 11:8 | 14:10 | 1.00 ** |
| BFMa | 12.84 ± 2.63 | ||
| UMRSa | 34.16 ± 4.06 | ||
| MDE/dysthymiab | 3 | 0 | 0.08** |
| Anxiety disorderb | 15 | 2 | <0.001** |
| OCDb | 5 | 1 | 0.07** |
| Addictionb | 1 | 0 | 0.44** |
| Medicationc | 9 | 0 | <0.001** |
aReported as mean ± Standard Error of the Mean.
bReported in effective.
cZonisamide (n = 4), Benzodiazepine (n = 4) Trihexyphenidyl (n = 1), Selective serotonin reuptake inhibitors (n = 2), Tetrabenazine (n = 1), Botulinic toxin injections (n = 2).
*ANOVA analysis.
**Fischer’s exact test.
Significant test results in bold.
DYT-SGCE, myoclonus dystonia; HV, healthy volunteers; R, righty; L, lefty; F, female; M, male; BFM, Burke-Marsden-Fahn scale; UMRS, Unified Myoclonus Rating scale; MDE, major depressive episode; OCD, obsessive-compulsive disorder.